Malignant Melanoma of the Oral Cavity: An Aggressive and Rare Entity.

Indian J Otolaryngol Head Neck Surg

Kasturba Medical College, Manipal, Karnataka 576104 India.

Published: October 2024

AI Article Synopsis

  • - Oral malignant melanoma is quite rare and very aggressive, leading to a poor prognosis overall.
  • - A 61-year-old woman had hyperpigmented and bleeding spots in her lower jaw (anterior mandible).
  • - Diagnosis was confirmed through microscopic analysis showing positive results with specific antibodies (HMB45 and S100 protein).

Article Abstract

It is exceptionally unusual to see oral malignant melanoma, which is highly aggressive with dismal prognosis. A 61-year-old female patient presented with hyperpigmented and hemorrhagic areas in the anterior mandible. Microscopically, positive Immunohistochemistry staining with monoclonal antibody Human Melanoma Black (HMB45) and S100 protein, confirmed the diagnosis as malignant melanoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456140PMC
http://dx.doi.org/10.1007/s12070-024-04899-yDOI Listing

Publication Analysis

Top Keywords

malignant melanoma
12
melanoma oral
4
oral cavity
4
cavity aggressive
4
aggressive rare
4
rare entity
4
entity exceptionally
4
exceptionally unusual
4
unusual oral
4
oral malignant
4

Similar Publications

The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview.

Curr Treat Options Oncol

January 2025

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, 6997801, Tel Aviv, Israel.

Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments. Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases.

View Article and Find Full Text PDF

Objectives: This study aimed to evaluate the incidence and clinical significance of coexistence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibody in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM).

Methods: We assessed a cohort of 246 consecutive patients with anti-MDA5 + DM. Clinical characteristics and survival rates were compared between patients with and without anti-ARS antibodies.

View Article and Find Full Text PDF

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.

Cancer Immunol Immunother

January 2025

Department of Dermatology and National Center for Tumor Diseases (NCT), Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.

Cytomegalovirus (CMV) infection or reactivation in immune-compromised individuals can lead to a wide range of severe complications including hepatitis. However, its relation with immune checkpoint inhibitors (ICIs) induced hepatitis (ICI-hepatitis) and tumor responses in advanced melanoma patients remains unclear. Hundred and ninety metastatic cutaneous melanoma patients (mCM) who received ICI treatment, with CMV IgG or IgM information available at baseline, were included in the study (Cohort 1).

View Article and Find Full Text PDF

Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!